ArticleBMC cancer2026
Prognostic factors and survival in elderly breast cancer patients: roles of age, stage and inflammatory markers.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer is a major clinical problem in elderly patients, yet data on prognostic factors and treatment outcomes in this population remain limited. This study investigated clinical characteristics, treatment patterns, and survival in elderly breast cancer patients, with focus on functional status, comorbidity burden, and inflammatory markers.
methodsThis retrospective study included 261 patients aged ≥ 65 years diagnosed with breast cancer at Dokuz Eylül University Medical Oncology Clinic between 2010 and 2023. Patients were stratified into two age groups (65-74 and ≥ 75 years). Clinicopathological characteristics, treatment modalities, ECOG performance status, Charlson Comorbidity Index (CCI), and the derived neutrophil-to-lymphocyte ratio (dNLR) were analyzed. Treatment comparisons were restricted to non-metastatic disease (stage I-III, n = 204). Survival was analyzed with Kaplan-Meier and log-rank tests. Receiver operating characteristic (ROC) analysis identified an optimal dNLR cutoff, and time-dependent ROC with inverse probability of censoring weighting assessed discriminatory performance over time. Multivariate Cox regression with backward likelihood ratio elimination identified independent prognostic factors; Harrell's concordance index was calculated for model validation.
resultsMedian follow-up was 142 months. No significant differences were observed between age groups regarding pathological features, receptor status, or comorbidities. However, patients aged ≥ 75 years were less likely to undergo primary surgery (p = 0.041), adjuvant chemotherapy (p = 0.001), or radiotherapy (p = 0.001). Median overall survival was 148 versus 87 months (p < 0.001). ROC identified an optimal dNLR cutoff of 1.74 (AUC 0.628); time-dependent AUCs were 0.772, 0.652, and 0.668 at 1, 3, and 5 years. LDH showed no significant discriminatory capacity. Multivariate analysis identified ECOG ≥ 2 (HR 2.89), CCI ≥ 3 (HR 2.12), stage IV (HR 7.43), dNLR > 1.74 (HR 2.14), TNBC (HR 2.30), age ≥ 75 (HR 1.52), and surgery (HR 0.53) as independent predictors of mortality. The full model achieved a C-index of 0.792.
conclusionElderly breast cancer patients are less frequently treated despite similar clinicopathological features. ECOG performance status, CCI, disease stage, dNLR, and clinical subtype are independent predictors of mortality. The prognostic impact of chronological age was substantially attenuated after adjusting for functional status and comorbidity, emphasizing that treatment decisions should be guided by comprehensive geriatric assessment rather than age alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.